Phenotypic and functional maturation of TCR gammadelta cells in the human thymus.

J Immunol

Department of Clinical Chemistry, Microbiology, and Immunology, University of Ghent, University Hospital, Belgium.

Published: May 1997

In contrast to thymic differentiation of TCR alphabeta cells, differentiation stages of TCR gammadelta cells are largely unknown. This report shows that CD1, a known marker of immature TCR alphabeta thymocytes, was expressed on some postnatal TCR gammadelta thymocytes. Only CD1+ TCR gammadelta thymocytes expressed recombination-activating gene-1 mRNA, and they were shown to differentiate into CD1- TCR gammadelta thymocytes. Functionally, sorted CD1- TCR gammadelta thymocytes proliferated in the presence of immobilized anti-CD3 Ab plus exogenous rIL-2 or rIL-15. Interestingly, in contrast to CD1- TCR alphabeta cells, CD1- TCR gammadelta thymocytes also proliferated extensively when cultured with exogenous rIL-2 or rIL-15 alone. FACS analysis as well as reverse transcription-PCR analysis showed that only CD1- TCR gammadelta thymocytes expressed IL-2Rbeta protein and mRNA. The differential expression of maturation markers, such as CD27, CD45RO, and CD45RA, as a function of expression of CD1 was similar in TCR gammadelta and TCR alphabeta thymocytes. An important exception is the expression of CD4 and CD8. Whereas TCR alphabeta thymocytes are mainly CD4-CD8 double positive at the immature CD1+ stage and CD4 or CD8 single positive at the mature CD1- stage, CD1(bright) TCR gammadelta thymocytes all expressed CD4, but only some of them expressed CD8. Some CD1- TCR gammadelta thymocytes also expressed CD8, but were negative for CD4. Collectively, our data clearly show that CD1 is a useful marker to distinguish immature human TCR gammadelta thymocytes from functional mature gammadelta cells based on recombination-activating gene-1 expression, in vitro differentiation, and phenotypic and functional characteristics.

Download full-text PDF

Source

Publication Analysis

Top Keywords

tcr gammadelta
48
gammadelta thymocytes
36
cd1- tcr
24
tcr alphabeta
20
thymocytes expressed
20
tcr
17
gammadelta
13
gammadelta cells
12
thymocytes
12
alphabeta thymocytes
12

Similar Publications

Human γδ T cells in the tumor microenvironment: Key insights for advancing cancer immunotherapy.

Mol Cells

January 2025

Laboratory of Host Defenses, Department of Biological Sciences, KAIST, Daejeon 34141, Republic of Korea; KAIST Institute of Health Science and Technology, KAIST, Daejeon 34141, Republic of Korea. Electronic address:

The role of γδ T cells in antitumor responses has gained significant attention due to their unique major histocompatibility complex (MHC)-independent killing mechanisms, which distinguish them from conventional αβ T cells. Notably, γδ tumor-infiltrating lymphocytes (TILs) have been identified as favorable prognostic markers in various cancers. However, γδ TIL subsets, including Vδ1, Vδ2, and Vδ3, exhibit distinct prognostic implications and phenotypes from one another within the tumor microenvironment (TME).

View Article and Find Full Text PDF

Lipopolysaccharide (LPS) is a potent endotoxin released at high concentrations in acute infections, causing massive host inflammatory response. Accumulating evidence indicates that dysbiosis-associated chronic low levels of circulating LPS can sustain a prolonged sterile low-grade inflammation that increases the risk of several non-communicable diseases. Interventions aimed at increasing the abundance of beneficial/probiotic bacteria, including , result in reduced inflammation, favoring metabolic and immune health.

View Article and Find Full Text PDF
Article Synopsis
  • The Centre of Excellence for the Technologies of Gene and Cell Therapy (CTGCT) has been established at the National Institute of Chemistry in Ljubljana, marking Slovenia’s first center dedicated to precision medicine and cutting-edge therapies.
  • The CTGCT aims to advance cancer immunotherapy and personalized treatments for genetic diseases by developing innovative biomedical tools and collaborating with international institutions for effective therapy development.
  • Its focus on translating research into practice, alongside partnerships with clinicians and patient organizations, positions the CTGCT as a key player in improving access to gene and cell therapies across Slovenia and the broader Eastern European region.
View Article and Find Full Text PDF

Structural characterization of two γδ TCR/CD3 complexes.

Nat Commun

January 2025

Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 10591, USA.

The T-cell receptor (TCR)/CD3 complex plays an essential role in the immune response and is a key player in cancer immunotherapies. There are two classes of TCR/CD3 complexes, defined by their TCR chain usage (αβ or γδ). Recently reported structures have revealed the organization of the αβ TCR/CD3 complex, but similar studies regarding the γδ TCR/CD3 complex have lagged behind.

View Article and Find Full Text PDF

γδ T cells in hematological malignancies: mechanisms and therapeutic strategies.

Blood Sci

January 2025

Department of Hematology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China. Hefei, Anhui 230001, China.

Article Synopsis
  • γδ T cells are a unique type of immune cells with both innate and adaptive characteristics, crucial for targeting and eliminating hematological cancers using various mechanisms and enhancing other immune responses.
  • They show strong antiviral capabilities after hematopoietic stem cell transplantation (HSCT), potentially improving patient outcomes.
  • Despite facing challenges like low prevalence in blood and varied subtypes, there are exciting strategies being explored for γδ T cell-based therapies, including clinical trials that assess their safety and effectiveness in treating blood cancers.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!